Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab', 'lymsm', 'lymphoma']
 shows us that relapse is uncommon in patients with large b-cell lymphoma who are in complete remission at the end of
fixed-course #glofitamab treatment #ash22 #lymsm 
Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.